ABSTRACT -The main focus of this repeated dose toxicity study was to determine the optimal administration period in terms of toxic effects on ovarian morphological changes. To assess the morphological and functional changes induced by anastrozole in ovaries, the compound was administered to female rats at dose levels of 0, 0.01, 0.1, 1 and 50 mg/kg for 2 or 4 weeks in the repeated dose toxicity study and at levels of 0, 0.01, 0.1, and 5 mg/kg from 2 weeks prior to mating to Day 7 of pregnancy in the female fertility study. In the repeated dose toxicity study, large abnormal atretic follicles, follicular cysts, a decrease in corpus luteum and depletion of developing corpus luteum were observed in the 1 and/or 50 mg/kg groups of both the 2-week and 4-week studies in a histopathological examination of the ovaries. In the female fertility study, the pregnancy rate was decreased in the 5 mg/kg group. Irregular estrous cycles, such as an extended cycle or no cycle, were observed in the 0.1 and 5 mg/kg groups. At necropsy, decreased numbers of implantations, corpora lutea and live fetuses were noted in the 1 and/or 5 mg/ -cient to detect ovarian toxicity of anastrozole in a repeated dose toxicity study.
INTRODUCTION
As a part of a collaborative study on toxicity related to female fertility, we performed experiments using anastrozole, a potent inhibitor of aromatase, a rate-limiting enzyme in transforming androgens to estrogens (Santen, 1993) . In the ovary, aromatase expression is detected in the granulosa cell (Sakurada et al., 2006) , and is essential for the maturation of follicles (Britt et al., 2000; Toda et al., 2001) . It has been reported that an aromatase inhibitor disturbed the estrous cycle and caused ovarian morphological changes such as follicular cysts in rats after a 90-day infusion (Mannerås et al., 2007) , and a 21-day oral administration (Kim et al., 2006) . Moreover, an aromatase knock-out female animal was shown to be totally infertile (Toda et al., 2001) . Because aromatase inhibitors are expected to have an impact on both ovarian morphology and female fertility, we chose anastrozole as the test compound.
The present study was designed to determine whether ovarian morphological changes in repeated dose toxicity studies, and whether effects of anastrozole on the female reproductive function in a female fertility study is predictable from the morphological changes.
MATERIALS AND METHODS

Test article
Anastrozole was obtained from LKT Laboratories, Inc. (St. Paul, MN, USA). Anastrozole was suspended in hydroxypropyl methylcellulose solution in 0.1% w/v polysorbate 80 in a volume of 0.1 ml/100 g body weight. Control animals were given the same amount of the vehicle solution.
Animals
SPF Fischer344 female rats (for the repeated dose toxicity studies) and SPF Sprague Dawley male and female rats (for the female fertility study) were purchased from Charles River Laboratories Japan, Inc. (Tokyo, Japan). The animals were housed in a room maintained at 20 -26°C and a relative humidity of 30 -70% with lighting from 7:00 to 19:00 and with 10 -15 ventilations per hour. All the animals were allowed free access to tap water and to commercial rodent chow, CRF-1 (Oriental Yeast Co., Ltd., Tokyo, Japan), for the repeated dose toxicity study and Certified Rodent Diet 5002 (PMI Nutrition International, Inc., St. Louis, MO, USA) for the female fertility study. This study was conducted in compliance with the following law and guidelines.
" 
Study design
Repeated dose toxicity studies
Anastrozole was orally administered to female rats at dose levels of 0, 0.01, 0.1, 1 and 50 mg/kg for 2 and 4 weeks. Each group consisted of 10 animals. The animals were observed daily for their general condition and their body weights were measured once every 3 to 4 days. Their estrous cycles were determined every day with vaginal smears in the last week of the 2-week study or in the last 2 weeks of the 4-week study. On the day of necropsy, all of the animals were anesthetized with ether and blood exsanguinated from the abdominal aorta. After exsanguination, the macroscopic examination was performed and the ovaries, uterus, vagina, liver and pituitary were Bilateral ovaries were transversally halved at dissection to observe the maximum area of the ovary. All of the organs were embedded in paraffin and histopathological specimens prepared and stained with hematoxylin and eosin (HE) according to standard procedures. Immunohistochemistry using Dako anti-Proliferation cell nuclear antigen (PCNA) antibody (clone: PC10) was also performed on the ovaries. The prepared specimens were examined histopathologically.
Female fertility study
Anastrozole was orally administered to female rats at dose levels of 0, 0.01, 0.1 and 5 mg/kg for 2 weeks before mating. Males were non-treated and were used only for mating purposes. After the 2-week administration, females were cohabited with non-treated males for up to 2 weeks. The daily dosing of anastrozole or vehicle was continued through the mating period and until Day 7 of pregnancy, or until the last day of the mating period if the animal did not copulate. Copulation was judged to have occurred when a vaginal plug was found or sperm was present in the smears. The animals were necropsied on Day 14 of pregnancy or on the last day of the mating period and the thoracic and abdominal organs were examined macroscopically. Then the number of corpora lutea, implantations, live embryos and dead embryos were counted, and conception and pregnancy rates calculated. In addition, a vaginal smear was collected from all females during the pre-mating period and estrous cycles evaluated. Each group consisted of 10 animals of each sex.
Statistical analyses
Statistical comparisons were made between treated groups and control groups. Differences were considered significant when P < 0.05. Data, including body weight at every measure time point, organ weight (absolute and relative to body weight), number of corpora lutea and implantations, number of live and dead embryos and mean estrous cycle (day) were examined by Bartlett-Dunnett test. First, the parameter was analyzed by Bartlett's of variance. The parameter was further analyzed by Dunnett's test when a set of variance was homogeneous and by Dunnett's rank test when it was not. For the rate of pre-implantation loss and post-implantation loss, Dunnett's rank test was applied. Chi-square test was used for rate of copulation, conception and animals with irregular estrous cycles.
RESULTS
Repeated dose toxicity study
During the dosing period, neither death nor marked change in general condition was observed in any of the groups treated with anastrozole in either the 2-week or 4-week study.
ues were observed in the 50 mg/kg group of the 2-week study, and in the 1 and 50 mg/kg groups of the 4-week study (Tables 1 and 2 ).
In terms of estrous cycle, all animals in the 50 mg/ kg group showed no or almost no estrous cycle, whereas none of the animals of the 0.01, 0.1 and 1 mg/kg group in both the 2 and 4 week studies showed any effects. (Tables  1 and 2 ).
Significant changes in mean organ weights were observed in the ovaries and liver in the 2-week study, and in the ovaries, uterus, liver and pituitary in the 4-week study (Tables 3 and 4 ).
In the histopathological examination, the criteria for 5, and the abnormalities observed in the ovaries, vagina and liver in both the 2-and 4-week studies were shown in Tables 6 and 7 . In the ovary, increase in large atretic follicle, which is the atretic follicle as large as the graa-2 weeks study and in the 1 and 50 mg/kg groups of the 4 weeks study (Fig. 1 ). In addition, increase of follicular than type 8 follicle (Pedersen and Peters, 1968 ) and surrounded by lack or thin granulosa layer, was observed in the 50 mg/kg group of both the 2-week and 4-week studies. Decrease in the corpus luteum was observed in the 1 and 50 mg/kg groups of the 2-week study and in the 50 mg/kg group of the 4-week study. Loss of the currently formed corpus luteum, which is newly formed after the last estrus, was observed in the 50 mg/kg groups of both 2-week and 4-week studies (Figs. 1-A and 1-B). In the vagina, mucinous degeneration of the epithelium and single-cell necrosis of the epithelium were observed in the 50 mg/kg groups of both 2-week and 4-week studies.
In the liver, hypertrophy of hepatocyte in the centrilobular zone was observed in the 50 mg/kg groups of both 2-week and 4-week studies.
Female fertility study
There were no deaths and no treatment-related abnormalities in the clinical signs in the females at any dose level. Higher values in mean body weight during the premating period compared to the control group were noted in females receiving 5 mg/kg. In the observation of the female estrous cycle during the pre-mating period, irregular estrous cycles, such as an extended estrous cycle or no estrous cycle, were observed in all the animals given 0.1 and 5 mg/kg. No remarkable abnormalities were detected in estrous cycle in animals given 0.01 mg/kg. Regarding reproductive potential, a decreased pregnancy rate was noted in the 5 mg/kg group. In the necropsy of the dams, a decreased number of corpora lutea was observed in the 5 mg/kg group and lower values in the number of implantations and the numbers of live embryos were noted in the 0.1 and 5 mg/kg groups. No changes were observed in animals given 0.01 mg/kg (Table 8) .
DISCUSSION
Anastrozole is a non-steroidal aromatase inhibitor which has been used to treat breast cancer. Since aromatase inhibitors block the synthesis of estrogens, these compounds have the potential to harm the female reproductive organs. In this study, we used anastrozole to determine the optimal administration period in terms of the effects on ovarian morphological changes in a general toxicity study. Moreover, No Observed Adverse Effect Level (NOAEL) for the repeated dose toxicity study focusing on the ovary and that for the female fertility study were also compared.
After anastrozole administration, morphological changes in the follicular maturation of large follicles, such as the large atretic follicle and follicular cyst, were observed in the repeated dose toxicity study. Small to medium follicles were intact. Aromatase expression is detected in the granulosa cell (Sakurada et al., 2006) , and is indispensable to the follicular maturation of large follicles (Britt et al., 2000) . Therefore, the maturation process of large follicles should be a target for aromatase inhibitors. In fact, the same follicular abnormalities as observed in this study were also reported in rats treated with other aromatase inhibitors (Mannerås et al., 2007) . Moreover, a preliminary hormone assay using a plasma sample obtained at necropsy was performed and the results showed increased testosterone levels in the 50 mg/kg group of the 2-week study and in the 1 and 50 mg/kg groups of the 4-week study (data not shown). Ehrmann et al. (1995) reported that excess androgens in the ovary may be associated with follicular cystic change. Hence, the increased androgen level may be one reason for the genesis of the large atretic follicle and the follicular cyst, which seemed to result in the increase in ovarian weights. Regarding the corpus luteum, there was no developing corpus luteum in either the 2-week or 4-week study. Accordingly, the late stage of follicular maturation and ovulation should be completely suppressed by anastrozole treatment. This speculation regarding anovulation was also supported by the 
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results of the estrous cycle examination, which showed there was no estrous phase in the 50 mg/kg group. We judged that the ovarian changes observed in this study, such as an increase of the large atretic follicle and follicular cyst, a decrease of the corpus luteum and depletion of the developing corpus luteum, are all caused by anastrozole. Therefore, the NOAEL for the repeated dose toxicity study focusing on the ovary was 1 mg/kg and 0.1 mg/ kg in the 2-week study and 4-week study, respectively. Other organs where histopathological changes were detected included the liver and vagina. In the liver, hypertrophy of hepatocyte was observed in the 50 mg/kg group in the pathogenesis of hepatic drug-metabolizing enzyme induction by anastrozole (Astra Zeneca Co., Ltd., London, UK). The increase in the organ weight of the liver may be attributed to this hypertrophy. In the vagina, mucinous degeneration and/or single cell degeneration were observed. Vaginal changes were also induced by tamoxifen treatment (Kim et al., 2006) , hence it is considered that the vaginal changes in this study were caused by disturbance of sexual hormones along with the anastrozole treatment. In the uterus and pituitary, there were no microscopic abnormal changes in the treated group, although the organ weights et al. (1993) . The mode of action seems to be based on the disturbance of female sexual hormones.
In the female fertility study, there were no deaths and no treatment-related abnormalities in the clinical signs in females at any dose level, although increased mean body weight during the pre-mating period was noted in females receiving 5 mg/kg. Letrozole, an aromatase inhibitor, has been reported to increase body weight in female rats (Sakurada et al., 2006) . Therefore, this change is considered to be one of the pharmacological properties of this class of compounds. In observation of the female estrous cycle, extended or no estrous cycle were observed in all animals given 0.1 mg/kg or higher. It has been reported that inhibition of aromatase results in increased serum levels of testosterone in rats because testosterone is a precursor of estrogen and is accumulated by aromatase inhibition (Kumru et al., 2007) . Furthermore, repeated administration of aromatase inhibitors to pregnant rats is suspected to decrease the serum progesterone levels in addition to lowering the estrogen level, since the number of corpora lutea is reduced as a consequence of anovulation or a decreased number of ovulations. Presumably, these sex hormone disturbances could be considered one of the causes of an irregular estrous cycle, although the sex hormone concentrations were not measured in the fertility study. Meanwhile, regarding the reproductive potential, decreased pregnancy rate was noted in the 5 mg/kg group. In the necropsy of the dams, a decreased number of corpora lutea was observed in the 5 mg/kg group and lower values in the number of implantations and number of live embryos were noted in the 0.1 and 5 mg/kg groups. As mentioned above, aromatase inhibitors suppress the ovulation in rats due to the lower biosynthesis of estrogen, which plays an important role in ovulation. Moreover, aromatase inhibition also affects implantation because estrogen is essential for implantation of blastocytes. Namely, the preovulatory estrogen surge causes a proliferation of epithelial cells in the uterus prior to and Johnson, 1986). For these reasons, the decreased number of corpora lutea, implantations and live embryos mainly seemed to be the result of the decreased estrogen level by aromatase inhibition. Based on these results, the NOAELs for the repeated dose toxicity in females, for the reproductive function in females and for the development of the next generation were all considered to be 0.01 mg/kg. In conclusion, it is proposed that a 2-week administraanastrozole in repeated dose toxicity study and the effects of anastrozole on female reproductive function in female fertility studies is predictable from the morphological changes in the repeated dose toxicity study. 3.4 36.7 1) n = 5. Estrous cycle was uncountable in 5 animals because estrus was recorded only once or none. 2) Irregular cycle means interval between estrous cycles was longer than 4 days, or anestrous.
